Stock exchanges & markets

Overview Watchlists

Sandoz wins Health Canada approval for generic semaglutide injection

18. Sep 2026

(AWP Alliance News) - Sandoz won Health Canada marketing authorization on Sept. 18, 2026 for a generic semaglutide injection, positioning it to launch an Ozempic equivalent in Canada for adults with type 2 diabetes. The company said the approval does not change its 2026 financial guidance, citing no expected material contribution this year.

Sandoz flagged the Canadian GLP-1 market at USD 2.6 billion.

https://www.publicnow.com/view/55F75B04D88E650FFE51E59BD24E229A728A0BDA…

Disclaimer: This news brief was created using generative artificial intelligence. Sandoz Group AG published the original content used to generate this news brief via EQS News on September 18, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now